🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with figures suggesting more than 82 million infections annually. Especially elevated rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This medication, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the drug firm Innoviva to see it through.

“This authorization represents a major breakthrough in the management of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Outcomes and Global Access

According to data detailed in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which uses an injection and a pill. The research involved nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced optimism. Access to a single-dose, oral treatment such as this is seen as a "revolutionary step" for public health efforts. This is considered essential to lessen the impact of the disease for patients and to stop the proliferation of untreatable gonorrhoea globally.